Ferruccio Ceriotti
Papers
1
Total Citations
6
H-Index
1
About
Ferruccio Ceriotti is a distinguished clinical biochemist whose research focuses on improving the early detection and monitoring of prostate cancer through novel biomarkers. His major contributions center on the clinical validation of prostate-specific antigen (PSA) isoforms, particularly the [‑2]proPSA (p2PSA) derivative, which offers superior specificity for clinically significant disease. In a landmark 2019 observational prospective cohort study, Ceriotti demonstrated that p2PSA can predict biochemical recurrence (BCR) of prostate cancer after radical prostatectomy significantly earlier than total PSA alone, addressing a critical unmet need in post-surgical surveillance. This work, which has garnered 6 citations, highlights his commitment to translating molecular diagnostics into practical tools that reduce unnecessary biopsies and overtreatment. Beyond this, Ceriotti has been instrumental in standardizing laboratory measurements and establishing reference intervals for tumor markers, ensuring reproducibility across clinical settings. His research bridges the gap between bench and bedside, offering clinicians more reliable indicators for treatment decisions. For students and researchers, Ceriotti exemplifies how rigorous biomarker validation can directly impact patient outcomes, making his work essential reading for anyone interested in precision oncology and clinical chemistry.
Research Focus
Key Achievements
Top Papers
- 1